In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA), with a $13 price …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on shares of TG Therapeutics Inc (NASDAQ:TGTX) with a …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in today with a few insights on Cytori Therapeutics Inc (NASDAQ:CYTX), after the company announced mature data and publication in …
On August 24, Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) announced two new clinical collaborations to expand on the company’s previous immuno-oncology combinations or drugs that fight …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on Bioline RX Ltd (NASDAQ:BLRX), after the company announced the initiation of the Phase …
In a research report released earlier today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of ImmunoCellular Therapeutics (NYSEMKT:IMUC) with …
In a research report published Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on shares of Cytokinetics, Inc. (NASDAQ:CYTK) with a price target …
In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma Inc (NASDAQ:GALE) with an $8.00 price target, after …
In a research report published Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celator Pharmaceuticals Inc (NASDAQ:CPXX) with a price target …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a favorable report on Peregrine Pharmaceuticals (NASDAQ:PPHM), after the company released its fiscal fourth-quarter and full-year 2015 results, posting EPS …
